Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
The net profit margin is 0.00% as of the fiscal period ended Tuesday, June 30, 2026.
Reported quarterly profit margin; no daily interpolation.
Limited quarterly history available
Profit Margin needs at least three reported quarters before a meaningful chart is shown.
NET PROFIT MARGIN
0.00%
NET PROFIT MARGIN AVG TTM
N/A
NET PROFIT MARGIN AVG 3Y
N/A
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
N/A
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+100.00%
vs the sector median at left
Kailera Therapeutics, Inc.
Market Cap
$1.42B
Net Profit Margin
0.00%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.41B
Net Profit Margin
-2728.04%
TTM Avg
-1093.44%
3Y Avg
-2386.05%
5Y Avg
-1590.70%
Market Cap
$1.42B
Net Profit Margin
82.37%
TTM Avg
-82.37%
3Y Avg
-592.43%
5Y Avg
-414.63%
Market Cap
$1.40B
Net Profit Margin
2.93%
TTM Avg
3.18%
3Y Avg
2.55%
5Y Avg
2.48%
Market Cap
$1.39B
Net Profit Margin
-10773.46%
TTM Avg
416506.27%
3Y Avg
203244.58%
5Y Avg
135206.06%
Market Cap
$1.44B
Net Profit Margin
-81.79%
TTM Avg
-93.52%
3Y Avg
-130.36%
5Y Avg
-119.92%
Market Cap
$1.44B
Net Profit Margin
6.59%
TTM Avg
2.75%
3Y Avg
2.46%
5Y Avg
3.07%
Market Cap
$1.45B
Net Profit Margin
-16.75%
TTM Avg
-1.75%
3Y Avg
-3.69%
5Y Avg
-6.61%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.42B | 0.00% | N/A | N/A | N/A |
| Taysha Gene Therapies, Inc. (TSHA)vs › | $1.41B | -2728.04% | -1093.44% | -2386.05% | -1590.70% |
| AnaptysBio, Inc. (ANAB)vs › | $1.42B | 82.37% | -82.37% | -592.43% | -414.63% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.42B | N/A | N/A | N/A | N/A |
| The Pennant Group, Inc. (PNTG)vs › | $1.40B | 2.93% | 3.18% | 2.55% | 2.48% |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.39B | -10773.46% | 416506.27% | 203244.58% | 135206.06% |
| Ultragenyx Pharmaceutical Inc. (RARE)vs › | $1.44B | -81.79% | -93.52% | -130.36% | -119.92% |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.44B | 6.59% | 2.75% | 2.46% | 3.07% |
| Certara, Inc. (CERT)vs › | $1.45B | -16.75% | -1.75% | -3.69% | -6.61% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.46B | -667.95% | 15.59% | 7.79% | 7.79% |
Operating Margin
0.0%
Net Profit Margin
0.0%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 0.00% |
| 2026-03-31 | 0.00% |
